Tilo Thottakara1, Felix W Friedrich2, Silke Reischmann3, Simon Braumann3, Saskia Schlossarek3, Elisabeth Krämer3, Denise Juhr4, Hartmut Schlüter5, Jolanda van der Velden6, Julia Münch7, Monica Patten7, Thomas Eschenhagen3, Christel Moog-Lutz8, Lucie Carrier9. 1. Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany;; University Heart Center Hamburg, Hamburg, Germany; 2. Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany;. Electronic address: f.friedrich@uke.de. 3. Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany; 4. Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 5. Institute of Clinical Chemistry, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6. Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, the Netherlands; ICIN-Netherlands Heart Institute, Utrecht, the Netherlands. 7. DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany;; University Heart Center Hamburg, Hamburg, Germany; 8. Institut de Pharmacologie et de Biologie Structurale, CNRS, Toulouse, France;; Université de Toulouse, UPS, Toulouse, France. 9. Department of Experimental Pharmacology and Toxicology, Cardiovascular Research Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;; DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany;. Electronic address: l.carrier@uke.de.
Abstract
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant disease with mutations in genes encoding sarcomeric proteins. Previous findings suggest deregulation of the ubiquitin proteasome system (UPS) in HCM in humans and in a mouse model of HCM (Mybpc3-targeted knock-in (KI) mice). In this study we investigated transcript levels of several muscle-specific E3 ubiquitin ligases in KI mice and aimed at identifying novel protein targets. METHODS AND RESULTS: Out of 9 muscle-specific E3 ligases, Asb2β was found with the lowest mRNA level in KI compared to wild-type (WT) mice. After adenoviral-mediated Asb2β transduction of WT neonatal mouse cardiomyocytes with either a WT or inactive Asb2β mutant, desmin was identified as a new target of Asb2β by mass spectrometry, co-immunoprecipitation and immunoblotting. Immunofluorescence analysis revealed a co-localization of desmin with Asb2β at the Z-disk of the sarcomere. Knock-down of Asb2β in cardiomyocytes resulted in higher desmin protein levels. Furthermore, desmin levels were higher in ventricular samples of HCM mice and patients than controls. CONCLUSIONS: This study identifies desmin as a new Asb2β target for proteasomal degradation in cardiomyocytes and suggests that accumulation of desmin could contribute to UPS impairment in HCM mice and patients.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is an autosomal-dominant disease with mutations in genes encoding sarcomeric proteins. Previous findings suggest deregulation of the ubiquitin proteasome system (UPS) in HCM in humans and in a mouse model of HCM (Mybpc3-targeted knock-in (KI) mice). In this study we investigated transcript levels of several muscle-specific E3 ubiquitin ligases in KI mice and aimed at identifying novel protein targets. METHODS AND RESULTS: Out of 9 muscle-specific E3 ligases, Asb2β was found with the lowest mRNA level in KI compared to wild-type (WT) mice. After adenoviral-mediated Asb2β transduction of WT neonatal mouse cardiomyocytes with either a WT or inactive Asb2β mutant, desmin was identified as a new target of Asb2β by mass spectrometry, co-immunoprecipitation and immunoblotting. Immunofluorescence analysis revealed a co-localization of desmin with Asb2β at the Z-disk of the sarcomere. Knock-down of Asb2β in cardiomyocytes resulted in higher desmin protein levels. Furthermore, desmin levels were higher in ventricular samples of HCM mice and patients than controls. CONCLUSIONS: This study identifies desmin as a new Asb2β target for proteasomal degradation in cardiomyocytes and suggests that accumulation of desmin could contribute to UPS impairment in HCM mice and patients.
Authors: Frederik Flenner; Birgit Geertz; Silke Reischmann-Düsener; Florian Weinberger; Thomas Eschenhagen; Lucie Carrier; Felix W Friedrich Journal: J Physiol Date: 2017-02-07 Impact factor: 5.182
Authors: Amelia A Glazier; Neha Hafeez; Dattatreya Mellacheruvu; Venkatesha Basrur; Alexey I Nesvizhskii; Lap Man Lee; Hao Shao; Vi Tang; Jaime M Yob; Jason E Gestwicki; Adam S Helms; Sharlene M Day Journal: JCI Insight Date: 2018-06-07
Authors: Jonathan R Davey; Kevin I Watt; Benjamin L Parker; Rima Chaudhuri; James G Ryall; Louise Cunningham; Hongwei Qian; Vittorio Sartorelli; Marco Sandri; Jeffrey Chamberlain; David E James; Paul Gregorevic Journal: JCI Insight Date: 2016-04-21
Authors: Felix W Friedrich; Frederik Flenner; Mahtab Nasib; Thomas Eschenhagen; Lucie Carrier Journal: Front Physiol Date: 2016-12-05 Impact factor: 4.566
Authors: Simon Braumann; Tilo Thottakara; Sabrina Stücker; Silke Reischmann-Düsener; Elisabeth Krämer; Julia Groß; Marc N Hirt; Shirin Doroudgar; Lucie Carrier; Felix W Friedrich Journal: Front Physiol Date: 2018-09-19 Impact factor: 4.566